[{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendia Pharmaceuticals \/ AcuteBio","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ AcuteBio"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Chinese Society of Cardiology | Lepu Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbin Medical University \/ Chinese Society of Cardiology | Lepu Medical Technology","highestDevelopmentStatusID":"11","companyTruncated":"Harbin Medical University \/ Chinese Society of Cardiology | Lepu Medical Technology"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Sahajanand Medical Technologies Limited","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Sahajanand Medical Technologies Limited","highestDevelopmentStatusID":"11","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Sahajanand Medical Technologies Limited"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Samjin pharm Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Samjin Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Samjin pharm Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Samjin Pharmaceutical"},{"orgOrder":0,"company":"St. Antonius Hospital","sponsor":"St. Antonius Hospital Research Fund | Ace pharmaceuticals | Allgen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"St. Antonius Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Antonius Hospital \/ St. Antonius Hospital Research Fund | Ace pharmaceuticals | Allgen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"St. Antonius Hospital \/ St. Antonius Hospital Research Fund | Ace pharmaceuticals | Allgen Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FARMAK, a.s \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Inapplicable"},{"orgOrder":0,"company":"Center for Bioequivalence Studies and Clinical Research","sponsor":"Ferozsons Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Center for Bioequivalence Studies and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center for Bioequivalence Studies and Clinical Research \/ Ferozsons Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Center for Bioequivalence Studies and Clinical Research \/ Ferozsons Laboratories"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Corona Remedies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Corona Remedies","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Corona Remedies"}]
Find Clinical Drug Pipeline Developments & Deals for Clopidogrel
Details :
Rozat Gold is a fixed dose combination medicine consisting aspirin, rosuvastatin & clopidogrel. It is indicated for the treatment of coronary artery diseases.
Details :
Plavix (clopidogrel) is a P2Y12 platelet inhibitor which is indicated for the treatment of in adult patients with moderate to high-risk transient ischemic attack.
Reset All
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
